



Lonza Shanghai International
Trading Ltd.
Room 2027, No.1 Ji Long Road
Shanghai Pilot Free Trade Zone,
CN-ShanghaiChina
contact.cn@Lonza.com

Shanghai 7 April 2017

Endotoxin Production Interruption Clarification

Dear Lonza's Customer

We have received many inquiries from customers asking if the LAL operations interruption is related to the FDA inspection in the Lonza Walkersville media production area and subsequent Warning Letter received in April 2017. This is an important point we wish to clarify. **The impact on LAL production and the current backorder situation are independent of the Warning Letter.** However, there are several actions being taken site-wide including in LAL operations, as part of the corrective actions to the Warning Letter. Additionally, the Warning Letter does not apply to any other Lonza manufacturing facility or business including Lonza Pharma Biotech contract development and manufacturing services

Best regards
Lonza Shanghai International Trading Ltd.

Edward Kung
Sales Director
Lonza Bioscience Solution, China